Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/29/2017
Trade Name:
Cubicin Injection
Generic Name or Proper Name (*):
daptomycin
Indications Studied:
Complicated skin and skin structure infections (cSSSI) in pediatric patients 1 to 17 years of age
Label Changes Summary:
*Safety and effectiveness in the treatment of cSSSI has been established in the age groups 1 to 17 years. Use in these age groups is supported by evidence from adequate and well-controlled studies in adults, with additional data from pharmacokinetic studies in pediatric patients, and data from a safety, efficacy and PK study in pediatric patients 1 to 17 years of age with cSSSI. * Safety and effectiveness in pediatric patients below the age of one year have not been established. Avoid use of Cubicin in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems observed in neonatal dogs. * Not indicated in pediatric patients with renal impairment because dosage has not been established in these patients. * The safety profile in pediatric patients was similar to that observed in adult patients. * Information on dosing, administration, adverse reactions, PK, and clinical trial. * Postmarketing study.
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B,P
Sponsor:
Cubist Pharmaceuticals, Inc.
NNPS:
FALSE
Therapeutic Category:
Antibiotic
-
-